# Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

> **NCT01164579** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 109 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Tasocitinib plus Methotrexate
- **DRUG:** Tofacitinib plus placebo methotrexate
- **DRUG:** Placebo tofacitinib plus Methotrexate

## Key facts

- **NCT ID:** NCT01164579
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2015-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01164579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01164579, "Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01164579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*